TABLE OF CONTENTS I
LIST OF FIGURES XXII
LIST OF CHARTS XXXI

EXECUTIVE SUMMARY 1

JAPAN INTERVENTIONAL CARDIOLOGY MARKET OVERVIEW 1

COMPETITIVE ANALYSIS 4

MARKET TRENDS 7

MARKET DEVELOPMENTS 9

MARKETS INCLUDED 10

PROCEDURES INCLUDED 11

VERSION HISTORY 11

RESEARCH METHODOLOGY 12
Step 1: Project Initiation & Team Selection 12
Step 2: Prepare Data Systems and Perform Secondary Research 15
Step 3: Preparation for Interviews & Questionnaire Design 17
Step 4: Performing Primary Research 18
Step 5: Research Analysis: Establishing Baseline Estimates 20
Step 6: Market Forecasts and Analysis 21
Step 7: Identify Strategic Opportunities 23
Step 8: Final Review and Market Release 24
Step 9: Customer Feedback and Market Monitoring 25

DISEASE OVERVIEW 26
2.1 BASIC ANATOMY 26
2.2 DISEASE TREATMENTS AND DIAGNOSTICS 28
2.2.1 General Diagnostics 28
2.2.2 Coronary Artery Disease (CAD) 28
2.2.3 Myocardial Infarction (MI) 29
2.2.4 Angina Pectoris 30
2.3 PATIENT DEMOGRAPHICS 31
2.3.1 General Statistics 31

PRODUCT ASSESSMENT 33
3.1 PRODUCT PORTFOLIOS 33
3.1.1 Coronary Catheters Market 33
3.1.1.1 Diagnostic Coronary Catheter 33
3.1.1.2 Interventional Coronary Catheters 34
3.1.1.3 Intravascular Ultrasound (IVUS) Catheter 34
3.1.1.4 Optical Coherence Tomography (OCT) Catheter 35
3.2 REGULATORY ISSUES AND RECALLS 41
3.2.1 Boston Scientific 41
3.2.1.1 Coronary Stent 41
3.2.1.2 PTCA Balloon Catheter 41
3.2.1.3 Interventional Coronary Catheters and Guidewires 42
3.2.1.4 Coronary Embolic Protection Device 43
3.2.2 Cardinal Health 43
3.2.2.1 Coronary Vascular Closure Device 43
3.2.3 Cook Medical 44
3.2.3.1 Coronary Stent 44
3.2.3.2 Interventional Coronary Catheters and Guidewires 44
3.2.4 Cordis (Cardinal Health) 45
3.2.4.1 PTCA Balloon Catheter/Dilation Catheters 45
3.2.4.2 Interventional Coronary Catheters and Guidewires 46
3.2.5 Medtronic 47
3.2.5.1 Coronary Stent 47
3.2.5.2 PTCA Balloon and Dilation Catheters 47
3.2.5.3 Interventional Coronary Catheters and Guidewires 48
3.2.6 Merit Medical Systems 51
3.2.6.1 Interventional Coronary Catheters and Guidewires 51
3.2.6.2 Coronary Introducer Sheath 53
3.2.7 Spectranetics 54
3.2.7.1 Coronary Atherectomy Device 54
3.2.8 St. Jude Medical (Abbott Laboratories) 55
3.2.8.1 Coronary Vascular Closure Device 55
3.2.8.2 Interventional Coronary Catheters and Guidewires 55
3.2.9 Vascular Solutions (Teleflex) 56
3.2.9.1 Interventional Coronary Catheters and Guidewires 56
3.2.10 Volcano Therapeutics (Philips Volcano) 57
3.2.10.1 Interventional Coronary Catheters and Guidewires 57
3.2.10.2 Intravascular Ultrasound (IVUS) Catheter 57
3.2.11 Other Companies 58
3.2.11.1 Coronary Stent and other Vascular Stents 58
3.2.11.2 PTCA balloon catheter 58
3.2.11.3 Interventional Coronary Catheters and Guidewires 59
3.2.11.4 Coronary Atherectomy Device 61
3.2.11.5 Coronary Introducer Sheath 62
3.2.11.6 Intravascular Ultrasound (IVUS) Catheter 62
3.3 CLINICAL TRIALS 63
3.3.1 Abbott Laboratories 63
3.3.1.1 Coronary Stent 63
3.3.2 Asahi Intecc 72
3.3.2.1 Interventional Coronary Catheters and Guidewires 72
3.3.3 B. Braun 73
3.3.3.1 Coronary Stent 73
3.3.3.2 PTCA balloon catheter 74
3.3.4 Biosensors 78
3.3.4.1 Coronary Stent 78
3.3.5 Biotronik 80
3.3.5.1 Coronary Stent 80
3.3.5.2 PTCA balloon catheter 83
3.3.6 Boston Scientific 84
3.3.6.1 Coronary Stent 84
3.3.6.3 PTCA balloon catheter 87
3.3.6.4 Coronary Embolic Protection Device 87
3.3.7 Medtronic 88
3.3.7.1 Coronary Stent 88
3.3.7.2 Interventional Coronary Catheters and Guidewires 91
3.3.7.3 Coronary Embolic Protection Device 92
3.3.8 St. Jude Medical (Abbott Laboratories) 93
3.3.8.1 Interventional Coronary Catheters and Guidewires 93
3.3.8.2 Intravascular Ultrasound (IVUS) Catheter 93
3.3.8.3 Optical Coherence Tomography Catheter 94
3.3.8.4 Fractional Flow Reverse (FFR) Catheter 94
3.3.9 Terumo Interventional Systems (TIS) 95
3.3.9.1 Interventional Coronary Catheters and Guidewires 95
3.3.9.2 Coronary Embolic Protection Device 95
3.3.10 Other Companies 96
3.3.10.1 Coronary Stent 96
3.3.10.2 PTCA balloon catheter 108
3.3.10.3 Interventional Coronary Catheters and Guidewires 109
3.3.10.4 Coronary Embolic Protection Device 112
3.3.10.5 Coronary Chronic Total Occlusion Crosser CTO 113
3.3.10.7 Fractional Flow Reserve (FFR) Guidewire 114
3.3.10.8 Optical Coherence Tomography (OCT) Guidewire 114

INTRAVASCULAR ULTRASOUND CATHETER MARKET 116
4.1 INTRODUCTION 116
4.1.1 Pre-Stenting Applications 116
4.1.2 Post-Stenting Applications 117
4.1.3 IVUS Penetration 117
4.2 MARKET OVERVIEW 118
4.3 MARKET ANALYSIS AND FORECAST 121
4.3.1 Total Intravascular Ultrasound Catheter Market 121
4.3.2 Rotational Intravascular Ultrasound Catheter Market 123
4.3.3 Phased Array Intravascular Ultrasound Catheter Market 125
4.4 DRIVERS AND LIMITERS 127
4.4.1 Market Drivers 127
4.4.2 Market Limiters 127
4.5 COMPETITIVE MARKET SHARE ANALYSIS 129

ABBREVIATIONS 132

APPENDIX: COMPANY PRESS RELEASES 134

Chart List
Chart 1 1: Interventional Cardiology Market by Segment, Japan, 2014 - 2024 3
Chart 1 2: Interventional Cardiology Market Overview, Japan, 2017 & 2024 3
Chart 4 1: Intravascular Ultrasound Catheter Market by Segment, Japan, 2014 - 2024 119
Chart 4 2: Intravascular Ultrasound Catheter Market Breakdown, Japan, 2017 120
Chart 4 3: Intravascular Ultrasound Catheter Market Breakdown, Japan, 2024 120
Chart 4 4: Total Intravascular Ultrasound Catheter Market, Japan, 2014 - 2024 122
Chart 4 5: Rotational Intravascular Ultrasound Catheter Market, Japan, 2014 - 2024 124
Chart 4 6: Phased Array Intravascular Ultrasound Catheter Market, Japan, 2014 - 2024 126
Chart 4 7: Leading Competitors, Intravascular Ultrasound Catheter Market, Japan, 2017 131

Figure List
Figure 1 1: Interventional Cardiology Market Share Ranking by Segment, Japan, 2017 (1 of 2) 4
Figure 1 2: Interventional Cardiology Market Share Ranking by Segment, Japan, 2017 (2 of 2) 5
Figure 1 3: Companies Researched in this Report, Japan, 2017 6
Figure 1 4: Factors Impacting the Interventional Cardiology Market by Segment, Japan (1 of 2) 7
Figure 1 5: Factors Impacting the Interventional Cardiology Market by Segment, Japan (2 of 2) 8
Figure 1 6: Recent Events in the Interventional Cardiology Market, Japan, 2014 - 2017 9
Figure 1 7: Interventional Cardiology Markets Covered, Japan, 2017 10
Figure 1 8: Interventional Cardiology Procedures Covered, Japan, 2017 11
Figure 1 9: Version History 11
Figure 3 1: Coronary Catheters Products by Company (1 of 3) 37
Figure 3 2: Coronary Catheters Products by Company (2 of 3) 38
Figure 3 3: Coronary Catheters Products by Company (3 of 3) 39
Figure 3 4: Imaging Catheter Products by Company 40
Figure 3 5: Class 1 Device Recall Boston Scientific Fetch 2 Aspiration Catheter 41
Figure 3 6: Class 2 Device Recall Boston Scientific, Small Peripheral Cutting BalloonTM 41
Figure 3 7: Class 2 Device Recall Boston Scientific, FlextomeTM Cutting BalloonTM 41
Figure 3 8: Class 2 Device Recall Boston Scientific ACUITY Pro Coronary Sinus Guide Catheter 42
Figure 3 9: Class 1 Device Recall Boston Scientific Fetch 2 Aspiration Catheter 42
Figure 3 10: Class 2 Device Recall Boston Scientific, FlextomeTM Cutting BalloonTM 42
Figure 3 11: Class 1 Device Recall RotaWire Elite and sireClip Torquer, Guidewire and Guidewire Manipulation Device, Floppy 43
Figure 3 12: Class 2 Device Recall MynxGrip Vascular Closure Device 43
Figure 3 13: Class 2 Device Recall Zilver 518RX Vascular Stent 44
Figure 3 14: Class 2 Device Recall Zilver 518 Vascular Self Expanding Stent 44
Figure 3 15: Class 2 Device Recall White Lumax Guiding Coaxial Catheter 44
Figure 3 16: Class 2 Device Recall Cordis POWERFLEX PRO PTA Dilatation Catheter 45
Figure 3 17: Class 2 Device Recall EMPIRA (TM) NC RX PTCA Dilatation Catheter 45
Figure 3 18: Class 2 Device Recall Cordis EMPIRA RX PTCA Dilatation Catheter 45
Figure 3 19: Class 2 Device Recall Cordis ADROIT 6F Guiding Catheter 46
Figure 3 20: Class 2 Device Recall Resolute Integrity Zotarolimuseluting Coronary Stent 47
Figure 3 21: Class 2 Device Recall PowerCross .018 OTW PTA Dilation Catheter 47
Figure 3 22: Class 2 Device Recall Ev3, Inc. (Medtronic) 47
Figure 3 23: Class 2 Device Recall NC Sprinter; Rapid Exchange Balloon Dilatation Catheter 48
Figure 3 24: Class 2 Device Recall Medtronic Launcher Coronary Guide Catheter 48
Figure 3 25: Class 2 Device Recall Launcher Coronary Guiding Catheter 48
Figure 3 26: Class 1 Device Recall ZINGER Steerable Guidewire 48
Figure 3 27: Class 1 Device Recall Cougar Nitinol Workhorse Guidewire 49
Figure 3 28: Class 1 Device Recall COUGAR Steerable Guidewire 49
Figure 3 29: Class 1 Device Recall THUNDER Steerable Guidewire 49
Figure 3 30: Class 1 Device Recall ProVia CROSSING GUIDEWIRE 49
Figure 3 31: Class 1 Device Recall ATTAIN HYBRID Guide Wire 50
Figure 3 32: Class 2 Device Recall Medtronic Zuma Guide Catheter 50
Figure 3 33: Class 2 Device Recall Merit Maestro Microcatheter 51
Figure 3 34: Class 2 Device Recall Merit Laureate Hydrophilic Guide Wire 51
Figure 3 35: Class 2 Device Recall Maestro Microcatheter, Merit Medical System 51
Figure 3 36: Class 2 Device Recall Performa Cardiac Multipack Catheter 52
Figure 3 37: Class 2 Device Recall Hydrophylic guidewire 52
Figure 3 38: Class 2 Device Recall PreludeEASE 53
Figure 3 39: Class 2 Device Recall Prelude Pro Sheath Introducter 53
Figure 3 40: Class 2 Device Recall Turbo Elite Atherectomy Catheter 54
Figure 3 41: Class 2 Device Recall ELCA Coronary Atherectomy Catheter 54
Figure 3 42: Class 2 Device Recall Vascular closure device 55
Figure 3 43: Class 3 Device Recall FastCath" Transseptal Guiding Introducer 55
Figure 3 44: Class 1 Device Recall TwinPass Dual Access Catheter 56
Figure 3 45: Class 2 Device Recall Percutaneous Catheter 56
Figure 3 46: Class 2 Device Recall Prestige Plus Wire 57
Figure 3 47: Class 2 Device Recall Volcano s5, s5i, CORE and CORE Mobile systems 57
Figure 3 48: Class 2 Device Recall Intravascular Ultrasound System 57
Figure 3 49: Class 2 Device Recall FLAIR Endovascular Stent Graft, Bard Peripheral Vascular 58
Figure 3 50: Class 1 Device Recall LifeStent Solo Vascular Stent, Bard Peripheral Vascular 58
Figure 3 51: Class 2 Device Recall PTA Balloon Dilatation Catheters 58
Figure 3 52: Class 2 Device Recall VIA 27 Microcatheters, Sequent Medical Inc. 59
Figure 3 53: Class 2 Device Recall Coronary Artery Perfusion Cannula with Balloon, Sorin Group USA, Inc. 59
Figure 3 54: Class 2 Device Recall Aortic Arch Cannula, Sorin Group USA, Inc. 59
Figure 3 55: Class 2 Device Recall Mallinckrodt Launcher Guiding Catheter, Stryker Sustainability Solutions 59
Figure 3 56: Class 2 Device Recall Distal Access Catheter (DAC), Concentric Medical Inc 60
Figure 3 57: Class 2 Device Recall Distal Access Catheter 60
Figure 3 58: Class 2 Device Recall Proplege Coronary Sinus Catheter, Edwards Lifesciences, LLC 60
Figure 3 59: Class 2 Device Recall Turbo Elite, ELCA Atherectomy Catheter, Spectranetics Corporation 61
Figure 3 60: Class 1 Device Recall Diamondback 360 Coronary Orbital Artherctomy System, Cardiovascular Systems, Inc. 61
Figure 3 61: Class 3 Device Recall Diamondback 360 Coronary Orbital Atherectomy System 61
Figure 3 62: Class 2 Device Recall VIA 27 Microcatheters, Sequent Medical Inc 62
Figure 3 63: Class 1 Device Recall Halo One ThinWalled Guiding Sheath, Bard Peripheral Vascular 62
Figure 3 64: Class 2 Device Recall SOUNDSTAR eco Catheter, Biosense Webster, Inc. 62
Figure 3 65: XIENCE Xpedition/Alpine in Routine Clinical Practice (IRIS XPEDITION) 63
Figure 3 66: Non-inferiority Study Comparing Firehawk Stent With Abbott Xience Family Stent (TARGET-AC) 63
Figure 3 67: Trial of MiStent Compared to Xience in Japan (DESSOLVEJ) 64
Figure 3 68: Effect and Efficacy of Xpedition™/Alpine™, Everolimus-eluting Stent for Coronary Atherosclerosis (HOST-ALPINE) 64
Figure 3 69: XIENCE Xpedition Everolimus-Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE Xpedition SV Japan PMS) 65
Figure 3 70: Absorb IV Randomized Controlled Trial 65
Figure 3 71: Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial (AIDA) 66
Figure 3 72: Xience Versus Synergy in Left Main PCI (IDEAL-LM) 66
Figure 3 73: Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent (TALENT) 67
Figure 3 74: XIENCE PRIME SV Everolimus Eluting Coronary Stent Post Marketing Surveillance (XIENCE PRIME SV PMS) 67
Figure 3 75: XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study (XP China SAS) 68
Figure 3 76: A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT) (ABSORB CHINA) 68
Figure 3 77: AVJ-301 Clinical Trial: A Clinical Evaluation of AVJ-301 (Absorb™ BVS) in Japanese Population (ABSORB JAPAN) 69
Figure 3 78: XIENCE PRIME Japan Post-Marketing Surveillance (PMS) 69
Figure 3 79: EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent, Performance, and Technique in Chronic Total Occlusions 70
Figure 3 80: Sirolimus-eluting Stent CALYPSO vs Everolimus-eluting Stent XIENCE (PATRIOT) 70
Figure 3 81: Stentys Coronary Stent System Clinical Trial in Patients With Acute Myocardial Infarction (APPOSITION V) 71
Figure 3 82: Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis (RESTORE) 71
Figure 3 83: The Asahi Intecc PTCA Chronic Total Occlusion Study (CTO-PCI) 72
Figure 3 84: Optilene® Suture for Coronary Artery Bypass Graft Surgery (OPTICABG) 73
Figure 3 85: Treatment of Coronary Artery Disease (CAD) With Bare Metal Stent (BMS) Followed by Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Eluting Stent 73
Figure 3 86: Paclitaxel Eluting Balloon Versus Drug Eluting Stent in Native Coronary Artery Stenoses of Diabetic Patients (PEPCAD IV) 74
Figure 3 87: Comparison of Agent™ and SeQuent® Please Paclitaxel Coated Balloon Catheters in Coronary In-stent Restenosis (AGENT-ISR) 74
Figure 3 88: Paclitaxel-Eluting Balloon Angioplasty and Coroflex™-Stents in the Treatment of Bifurcated Coronary Lesions (PEPCAD V) 75
Figure 3 89: The Paclitaxel-Eluting Percutaneous Coronary Angioplasty (PTCA)-Balloon Catheter for the Treatment of Coronary Bifurcations (PEPCAD-BIF) 75
Figure 3 90: INDICOR The Paclitaxel-Eluting PTCA-Balloon Catheter in Combination With a Cobalt-Chromium Stent (INDICOR) 76
Figure 3 91: A Safety and Efficacy Study of Paclitaxel-eluting Balloon to Paclitaxel-eluting Stent (PEPCAD) 76
Figure 3 92: The Paclitaxel-Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) - Balloon Catheter in Coronary Artery Disease to Treat Chronic Total Occlusions (PEPCAD-CTO) 77
Figure 3 93: PEPCAD I. The Paclitaxel-Eluting PTCA-Balloon Catheter to Treat Small Vessel 77
Figure 3 94: LEADERS FREE II: BioFreedom™ Pivotal Study 78
Figure 3 95: BioFreedom US IDE Feasibility Trial 78
Figure 3 96: A Randomized Clinical Evaluation of the BioFreedom™ Stent (Leaders Free) 79
Figure 3 97: Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease (ABSORB-LONG) 80
Figure 3 98: BIOTRONIK Orsiro Pre-Marketing Registration (BIOFLOW-VI) 80
Figure 3 99: Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions 81
Figure 3 100: BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III French Satellite 81
Figure 3 101: BIOHELIX-I Bare Metal Stent Study (BIOHELIX-I) 82
Figure 3 102: BIOFLOW III Asia Registry 82
Figure 3 103: BIOFLOW-III Israel Satellite Registry 82
Figure 3 104: Study of Vascular Healing With the Combo Stent Versus the Everolimus Eluting Stent in ACS Patients by Means of OCT (REMEDEE-OCT) 83
Figure 3 105: Drug Eluting Pantera Lux Catheter Registry 83
Figure 3 106: Post-Approval Study of PROMUS Element™ in China (PEChina) 84
Figure 3 107: EVOLVE China Clinical Trial (EVOLVE China) 84
Figure 3 108: EVOLVE Short DAPT Study 85
Figure 3 109: PROMUS Element Plus US Post-Approval Study 85
Figure 3 110: The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s) 86
Figure 3 111: SYNERGY China: Assess SYNERGY Stent in China 86
Figure 3 112: Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter 87
Figure 3 113: WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation 87
Figure 3 114: Safety and Efficacy of the CRE8 Stent for the Treatment of De Novo Coronary Artery Lesions 88
Figure 3 115: RESOLUTE ONYX Post-Approval Study (ONYX PAS) 88
Figure 3 116: Medtronic RevElution Trial (RevElution) 89
Figure 3 117: The European Bifurcation Club Left Main Study (EBC MAIN) 89
Figure 3 118: Medtronic Resolute Onyx 2.0 mm Clinical Study 89
Figure 3 119: Medtronic Resolute Onyx Core (2.25 mm - 4.0 mm) Clinical Study 90
Figure 3 120: Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use (CHINA RESOLUTE INTEGRITY STUDY) 90
Figure 3 121: An Evaluation of the Commercially Available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System (RI-US) 91
Figure 3 122: Randomized Comparison of JUDkins vs tiGEr Catheter in Coronary Angiography Via the Right Radial Artery: the JUDGE Study (JUDGE) 91
Figure 3 123: Atrial Fibrillation Detected by Continuous ECG Monitoring (LOOP) 92
Figure 3 124: Substrate Targeted Ablation Using the FlexAbility™ Ablation Catheter System for the Reduction of Ventricular Tachycardia (STAR-VT) 93
Figure 3 125: ILUMIEN III: OPTIMIZE PCI 93
Figure 3 126: ILUMIEN III: OPTIMIZE PCI 94
Figure 3 127: Portuguese Study on The Evaluation of FFR Guided Treatment of Coronary Disease (POST-IT) 94
Figure 3 128: Randomized Comparison of JUDkins vs tiGEr Catheter in Coronary Angiography Via the Right Radial Artery: the JUDGE Study (JUDGE) 95
Figure 3 129: Evaluation of the Roadsaver Stent Used in Conjunction With the Nanoparasol Embolic Protection System for Carotid Artery Stenosis 95
Figure 3 130: Firehawk™ Coronary Stent System in the Treatment of Total Coronary Artery Occlusion Lesion(s) 96
Figure 3 131: Safety and Efficacy Study of the Amaranth Medical MAGNITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT III) 96
Figure 3 132: Trial of MiStent Compared to Xience in Japan (DESSOLVEJ) 97
Figure 3 133: MedJ-01 Ridaforolimus Eluting Coronary Stent System Trial (JNIR) (JNIR) 97
Figure 3 134: Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation 98
Figure 3 135: BIONICS - Pharmacokinetics (PK) Trial (BIONICS) 98
Figure 3 136: Safety and Efficacy Study of the Amaranth Medical APTITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT II) 98
Figure 3 137: Evaluation of New Specifications (2.25mm) of FirehawkTM in the Treatment of Coronary Heart Disease ( Firehawk_2.25 ) 99
Figure 3 138: Evaluation of New Specifications (38mm) of FirehawkTM in the Treatment of Coronary Heart Disease (Firehawk_38) 99
Figure 3 139: Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent (MEND II) 100
Figure 3 140: Safety and Efficacy Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT) 100
Figure 3 141: Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold (FANTOM II), Reva Medical 100
Figure 3 142: Pilot Study of the Fantom Bioresorbable Scaffold (FANTOM I) (FANTOM I), Reva Medical 101
Figure 3 143: NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial 101
Figure 3 144: A Prospective, Single-arm, Multi-centre, Observational, Real World Registry (Morpheus) 102
Figure 3 145: Safety and Efficacy Study of the Svelte Drug-Eluting Coronary Stent Delivery System (DIRECT II) 102
Figure 3 146: First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme and Resolute Integrity in Patients With de Novo Coronary Artery Stenosis 103
Figure 3 147: eTryton Left Main Registry Tryton Side Branch Stent® Tmt of Denovo CAD in LM and CFX Arteries (eTRYTONLM) 103
Figure 3 148: An Evaluation of BioMime™ - Sirolimus Eluting Coronary Stent in a Multi- Centre Study The BioMime™1 Trial (MeriT-II) 104
Figure 3 149: An BioMime Vs. Xience Randomised Control Clinical Study (meriT-V) 104
Figure 3 150: BIONICS Israel Trial 105
Figure 3 151: Elixir Medical Clinical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System 105
Figure 3 152: Sapphire II PRO US Clinical Study 106
Figure 3 153: Axetis Inert Coronary Stent System First In Man Clinical Investigation (AXETIS FIM) 106
Figure 3 154: Shockwave Coronary Rx Lithoplasty® Study (Disrupt CAD I) 106
Figure 3 155: Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation 107
Figure 3 156: Procedural Advantages of a Novel Drug-Eluting Coronary Stent 107
Figure 3 157: Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study 108
Figure 3 158: Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter (VasoguardTM) in the Treatment of Small Coronary Vessel Stenosis With a Common Coronary Balloon Catheter (Maverick2) 108
Figure 3 159: Drug Eluting Balloon for Prevention of Constrictive Remodeling 109
Figure 3 160: Compare the Efficacy and Safety of RESTORE DEB and SeQuent® Please in Chinese Patient With Coronary In-stent Restenosis 109
Figure 3 161: Real-time MRI Right Heart Catheterization Using Passive Catheters 110
Figure 3 162: A Prospective, Multi-Center, Pivotal Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter in Facilitating Crossing Chronic Total Occlusion (CTO) Coronary Lesions 110
Figure 3 163: Safety and Feasibility of Using a Single Transradial Guiding Catheter for Primary PCI (RAPID) 111
Figure 3 164: A Prospective, First in Man Study to Evaluate the Safety and Performance of the NovaCross™ Micro-catheter 111
Figure 3 165: Performance of the CARDIOGARD Cannula (GECG) 112
Figure 3 166: DEFLECT II: A Study to Evaluate the Safety and Performance of the TriGuard™HDH in Patients Undergoing TAVR 112
Figure 3 167: Use of the GARDEX™ Embolic Protection Device During Percutaneous Coronary Interventions of Saphenous Vein Graft 113
Figure 3 168: Coherex WAVECREST I Left Atrial Appendage Occlusion Study 113
Figure 3 169: Trial to Compare FFR Measurement With a Non-Side-Hole Guide Catheter Vs. a Side-Hole Guide Catheter 114
Figure 3 170: Prospective Randomized Optical Coherence Tomography Oslo tRial (PROCTOR) 114
Figure 3 171: Optical Coherence Tomography Guided Percutaneous Coronary Intervention With Stent Implantation (OCTACS) 115
Figure 4 1: Intravascular Ultrasound Catheter Market by Segment, Japan, 2014 - 2024 (JP¥M) 118
Figure 4 2: Intravascular Ultrasound Catheter Market by Segment, Japan, 2014 - 2024 (US$M) 118
Figure 4 3: Total Intravascular Ultrasound Catheter Market, Japan, 2014 - 2024 121
Figure 4 4: Rotational Intravascular Ultrasound Catheter Market, Japan, 2014 - 2024 123
Figure 4 5: Phased Array Intravascular Ultrasound Catheter Market, Japan, 2014 - 2024 125
Figure 4 6: Drivers and Limiters, Intravascular Ultrasound Catheter Market, Japan, 2017 128
Figure 4 7: Leading Competitors, Intravascular Ultrasound Catheter Market, Japan, 2017 130
Figure 6 1: Press Release Summary 134

Companies
• The "Japan Market Report Suite for Interventional Cardiology Devices 2018 - MedSuite" includes analysis on the following companies currently active in this market:
• Abbott
• Boston Scientific
• Terumo
• Medtronic
• Philips Volcano
• Goodman Co.
• Cardinal Health
• Nipro/InfraReDx
• Asahi

Others include: B. Braun, Biosensors International Group Ltd., Biotronik, C.R. Bard, Cardiovascular Systems Inc., Cook Medical, Merit Medical, Olympus, Opsens, Stentys, Straub Medical, Teleflex, W. L. Gore, etc.
• *Not all companies are currently active in every segment or sub-report from this suite. For more details contact an iData Research Product Advisor.